IP Library Granted Patent US 8,962,263
Granted Patent B2
US 8,962,263 · App. 13/094,735 · Granted Feb 24, 2015

Methods and compositions for detecting the activation state of multiple proteins in single cells

Inventors: Omar D. Perez (Stanford, CA); Garry P. Nolan (San Francisco, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
G01N33/5302C12Q1/485G01N33/5008G01N33/5041G01N33/5091G01N33/5094G01N33/54313G01N33/573G01N33/582G01N2333/91205G01N2333/96466Y10S435/973
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,962,263
App. No.
13/094,735
Granted
Feb 24, 2015
Kind
B2
Abstract

The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.

Claims (19)

1. A composition comprising:

a first activation state specific binding element that is specific for an isoform corresponding to an activation state of a first activatable element; and

a second activation state specific binding element that is specific for an isoform corresponding to an activation state of a second activatable element,

wherein the first and second activation state specific binding elements are to be distinguishably detectable from one another, the first and second activatable elements are different from one another, and the first and the second activation state-specific binding elements are configured to detect binding to their corresponding activatable elements simultaneously or sequentially in single cells.

2. The composition according to claim 1 , wherein the first and second activation state specific binding elements are antibodies or binding fragments thereof.

3. The composition according to claim 1 , wherein the first and second activation state specific binding elements are labeled and the labels are distinguishable from one another.

4. The composition according to claim 3 , wherein the first and second activation state specific binding elements are labeled with a directly detectable label.

5. The composition according to claim 4 , wherein the directly detectable label is a fluorescent label.

6. The composition according to claim 3 , wherein the first and second activation state specific binding elements are labeled with an indirectly detectable label.

7. The composition according to claim 6 , wherein the indirectly detectable label is an enzyme.

8. The composition according to claim 1 , wherein the composition further comprises a bioactive agent.

9. The composition according to claim 8 , wherein the bioactive agent activates a signaling pathway.

10. The composition according to claim 9 , wherein the bioactive agent is selected from the group consisting of polypeptides, nucleic acids and small binding molecules.

11. The composition according to claim 1 , wherein the composition further comprises a fixation reagent.

12. The composition according to claim 1 , wherein the composition further comprises a permeabilizing reagent.

13. The composition according to claim 1 , wherein the composition is present in a vessel.

14. The composition according to claim 1 , wherein the activation state of at least one activatable element of the first and second activatable elements is the phosphorylation state of the activatable element, and wherein the binding element that is specific for the activation state of the activatable element is specific for the phosphorylation state of the activatable element.

15. The composition according to claim 1 , wherein the activation state of the first and second activatable elements is the phosphorylation state of the first and second activatable elements, and

wherein the binding element that is specific for the activation state of the first activatable element is specific for the phosphorylation state of the first activatable element, and the binding element that is specific for the activation state of the second activatable element is specific for the phosphorylation state of the second activatable element.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2011
From: PEREZ, OMAR D.; NOLAN, GARRY P.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 027007/0973 →
CONFIRMATORY LICENSE Recorded Aug 29, 2011
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026820/0688 →
Continuity (5)
Division 12372670 · Feb 17, 2009
Continuation 10193462 · Jul 10, 2002
Provisional Application 60304434 · Jul 10, 2001
Provisional Application 60310141 · Aug 2, 2001
Related Publication 20120309026A1 · Dec 6, 2012